Aptose Biosciences Inc APTO:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/18/22 EDT
1.05quote price arrow down-0.10 (-8.70%)
Volume
113,716
52 week range
0.90 - 5.78
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.05
  • 52 Week High5.78
  • 52 Week High Date06/08/21
  • 52 Week Low0.90
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap96.84M
  • Shares Out92.23M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta1.49
  • YTD % Change-22.22

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.05
  • 52 Week High5.78
  • 52 Week High Date06/08/21
  • 52 Week Low0.90
  • 52 Week Low Date05/12/22
  • Market Cap96.84M
  • Shares Out92.23M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta1.49
  • YTD % Change-22.22

RATIOS/PROFITABILITY

  • EPS (TTM)-0.67
  • P/E (TTM)-1.56
  • Fwd P/E (NTM)-1.73
  • EBITDA (TTM)-60.547M
  • ROE (TTM)-69.39%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/01/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aptose Biosciences Inc

There is no recent news for this security.

Profile

MORE
Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is...
William Rice Ph.D.
Chairman of the Board, President, Chief Executive Officer, Chief Accounting Officer
Address
251 Consumers Rd Suite 1105
North York, ON
M2J 4R3
Canada